<DOC>
	<DOCNO>NCT01104649</DOCNO>
	<brief_summary>The hereditary cerebellar ataxia include diverse neurodegenerative disorder . Hereditary ataxia divide autosomal dominant ataxia ( ADCAs ) , autosomal recessive ataxia ( ARCAs ) , X-linked , mitochondrial ataxias basis mode inheritance . The key feature disorder ataxia typically characterised poor balance , hand incoordination , postural kinetic tremor , dysarthria dysphagia . To date treatment show slow progression disease symptomatic therapy limit option partially effective . Purkinje cell project inhibitory signal deep cerebellar nucleus ( DCN ) critical role cerebellar function motor performance . DCN neuron fire spontaneously absence synaptic input Purkinje neuron modulation DCN response Purkinje input believe responsible coordination movement , uncontrolled spontaneous fire DCN neuron may underlay cerebellar ataxia . Recent study demonstrate small-conductance calcium-activated potassium ( SK ) channel inhibitor able increase DCN fire rate . Since SK channel critical regulator DCN fire rate , SK openers drug riluzole may reduce neuronal hyperexcitability thereby useful therapy cerebellar ataxia . On base investigator publish pilot study patient chronic cerebellar ataxia ( Ristori et al. , Neurology 2010 ) investigate safety efficacy riluzole placebo administration 8 week . The result demonstrate significative improvement International Cooperative Ataxia Rating Scale ( ICARS ) global score four week 8 week riluzole arm . The present protocol aim verify safety efficacy riluzole administration longer period , large sample size patient , stringent diagnostic criterion ( hereditary cerebellar ataxia ) , respect pilot study . Sixty patient enrol double-blind , placebo-controlled trial . By central randomisation , patient take 50 mg riluzole placebo twice daily 12 month . Treatment effect assess compare Scale Assessment Rating Ataxia ( SARA ) treatment therapy month 3 12 .</brief_summary>
	<brief_title>Efficacy Riluzole Hereditary Cerebellar Ataxia</brief_title>
	<detailed_description />
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Spinocerebellar Degenerations</mesh_term>
	<mesh_term>Riluzole</mesh_term>
	<criteria>Patients genetically confirm diagnosis hereditary cerebellar ataxia Concomitant experimental therapy ataxia Serious systemic illness Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Spinocerebellar ataxia</keyword>
	<keyword>Friedreich ataxia</keyword>
</DOC>